Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20599446 | 0.92 | ALDH1A1 (0.46) | DDB1CRBNALDH1A1MEN1KMT2A | |
| SCHEMBL1256462 | 0.86 | ALDH1A1 (0.51) | DDB1CRBNALDH1A1MEN1KMT2A | |
| SCHEMBL18692576 | 0.84 | ALDH1A1 (0.53) | DDB1CRBNALDH1A1KMT2ANR1H2 | |
| SCHEMBL12621202 | 0.84 | ALDH1A1 (0.53) | DDB1CRBNALDH1A1KMT2A | |
| SCHEMBL15114589 | 0.83 | KMT2A (0.51) | DDB1CRBNALDH1A1MEN1KMT2A | |
| SCHEMBL20221555 | 0.83 | ALDH1A1 (0.51) | DDB1CRBNALDH1A1 | |
| SCHEMBL16837713 | 0.82 | DDB1 (0.41) | DDB1CRBNALDH1A1MEN1KMT2A | |
| SCHEMBL19843713 | 0.82 | MEN1 (0.45) | DDB1CRBNALDH1A1MEN1KMT2A | |
| SCHEMBL6709368 | 0.79 | ALDH1A1 (0.54) | DDB1CRBNALDH1A1MEN1KMT2A | |
| SCHEMBL16837719 | 0.78 | DDB1 (0.41) | DDB1CRBNALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190734-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | Selcia Ltd. (GB) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190734-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | DDB1 1828/4885CRBN 1458/4885ALDH1A1 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.